| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6869939 | BAXTER HLTHCARE | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
May, 2022
(1 year, 11 months ago) | |
| US7635773 | BAXTER HLTHCARE | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(4 years from now) | |
Nexterone is owned by Baxter Hlthcare.
Nexterone contains Amiodarone Hydrochloride.
Nexterone has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Nexterone are:
- US6869939
Nexterone was authorised for market use on 24 December, 2008.
Nexterone is available in injectable;injection dosage forms.
The generics of Nexterone are possible to be released after 13 March, 2029.
Drugs and Companies using AMIODARONE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 December, 2008
Treatment: NA
Dosage: INJECTABLE;INJECTION
More Information on Dosage
NEXTERONE family patents
